In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing | Zendy

Rafael A. Guerra | Zendy; Marcos P. Silva | Zendy; Taís C. Silva | Zendy; M. C. Salvadori | Zendy; F. S. Teixeira | Zendy; Rosimeire Nunes de Oliveira | Zendy; Jefferson Almeida Rocha | Zendy; Pedro Luiz Silva Pinto | Zendy; Josué de Moraes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing

Author(s) -

Rafael A. Guerra,

Marcos P. Silva,

Taís C. Silva,

M. C. Salvadori,

F. S. Teixeira,

Rosimeire Nunes de Oliveira,

Jefferson Almeida Rocha,

Pedro Luiz Silva Pinto,

Josué de Moraes

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01722-18

Subject(s) - spironolactone , in vivo , drug repositioning , pharmacology , praziquantel , schistosomiasis , drug , biology , schistosoma mansoni , repurposing , medicine , immunology , helminths , microbiology and biotechnology , aldosterone , ecology

Schistosomiasis is a parasitic flatworm disease that infects over 200 million people worldwide, especially in poor communities. Treatment and control of the disease rely on just one drug, praziquantel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research